AI Summary
Researchers have found a new treatment for cytokine release syndrome (CRS) that reduces inflammation caused by interleukin-6, without the side effects of previous therapies.
Researchers have discovered a novel treatment to relieve cytokine release syndrome (CRS), a life-threatening inflammation triggered by a serious infection or severe burn. Treatment with a short-acting antibody reduces the inflammatory effects of interleukin-6, a key cytokine in CRS while avoiding the side effects associated with previous longer-acting therapies.